Therefore, the anemia of CKD is a potent stimulator of FGF23, as improvement of iron utilization via exogenous EPO administration, or endogenous EPO stimulation in mice treated with a HIF‐PHDi, markedly attenuated the increase in circulating iFGF23 concentrations. This evidence concerns the gene FGF23 and chronic kidney disease.